Analysis of factors associated with blood pressure reduction and serum potassium elevation in hypertensive patients treated with esaxerenone (CS-3150) -Integrated analysis from CS-3150 phase 3 studies
Not Applicable
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000047026
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1472
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy endpoint; Change in office sitting BP (systolic BP and diastolic BP) from baseline to Week 12 Safety endpoint; Number of patients with following serum potassium levels (1) 5.5 mEq/L and more (2) 6.0 mEq/L and more, or 5.5 mEq/L and more on two consecutive occasions
- Secondary Outcome Measures
Name Time Method